Hemostatic Agents for Bleeding: Recombinant-Activated Factor VII and Beyond

 

 Buy Article Permissions and Reprints

Abstract

A rapid restoration of hemostasis should be regarded as a primary goal for management of critical bleeding, which often represents a life-threatening condition. Among the various therapeutic strategies available in this clinical setting, we aim to summarize in this narrative review the current status on the use of recombinant-activated factor VII and prothrombin complex concentrates. The safety and effectiveness of these hemostatic agents in reversal of the anticoagulant effects of vitamin K antagonists will be also explored. In addition, their role in the management of acute bleeding associated with the newer direct oral anticoagulants dabigatran, rivaroxaban, and apixaban will be analyzed in a dedicated section.

• References

• 1 Mannucci PM, Levi M. Prevention and treatment of major blood loss. N Engl J Med 2007; 356 (22) 2301-2311
  CrossrefPubMedGoogle Scholar
• 2 Schulman S. Pharmacologic tools to reduce bleeding in surgery. Hematology (Am Soc Hematol Educ Program) 2012; 2012: 517-521
  PubMedGoogle Scholar
• 3 Kozek-Langenecker SA, Afshari A, Albaladejo P , et al. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol 2013; 30 (6) 270-382
  CrossrefPubMedGoogle Scholar
• 4 Franchini M, Lippi G. Recent improvements in the clinical treatment of coagulation factor inhibitors. Semin Thromb Hemost 2009; 35 (8) 806-813
  Article in Thieme ConnectPubMedGoogle Scholar
• 5 Franchini M, Mannucci PM. Inhibitors of propagation of coagulation (factors VIII, IX and XI): a review of current therapeutic practice. Br J Clin Pharmacol 2011; 72 (4) 553-562
  CrossrefPubMedGoogle Scholar
• 6 Franchini M. The modern treatment of haemophilia: a narrative review. Blood Transfus 2013; 11 (2) 178-182
  PubMedGoogle Scholar
• 7 Franchini M, Coppola A, Tagliaferri A, Lippi G. FEIBA versus NovoSeven in hemophilia patients with inhibitors. Semin Thromb Hemost 2013; 39 (7) 772-778
  Article in Thieme ConnectPubMedGoogle Scholar
• 8 Franchini M, Lippi G. Recombinant activated factor VII: mechanisms of action and current indications. Semin Thromb Hemost 2010; 36 (5) 485-492
  Article in Thieme ConnectPubMedGoogle Scholar
• 9 Franchini M, Lippi G. Acquired factor VIII inhibitors. Blood 2008; 112 (2) 250-255
  CrossrefPubMedGoogle Scholar
• 10 Coppola A, Favaloro EJ, Tufano A, Di Minno MN, Cerbone AM, Franchini M. Acquired inhibitors of coagulation factors: part I-acquired hemophilia A. Semin Thromb Hemost 2012; 38 (5) 433-446
  Article in Thieme ConnectPubMedGoogle Scholar
• 11 Hoffman M, Dargaud Y. Mechanisms and monitoring of bypassing agent therapy. J Thromb Haemost 2012; 10 (8) 1478-1485
  CrossrefPubMedGoogle Scholar
• 12 ten Cate H, Bauer KA, Levi M , et al. The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor. J Clin Invest 1993; 92 (3) 1207-1212
  CrossrefPubMedGoogle Scholar
• 13 Roberts HR, Monroe DM, White GC. The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood 2004; 104 (13) 3858-3864
  CrossrefPubMedGoogle Scholar
• 14 Butenas S, Brummel KE, Branda RF, Paradis SG, Mann KG. Mechanism of factor VIIa-dependent coagulation in hemophilia blood. Blood 2002; 99 (3) 923-930
  CrossrefPubMedGoogle Scholar
• 15 Lisman T, Mosnier LO, Lambert T , et al. Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A. Blood 2002; 99 (1) 175-179
  CrossrefPubMedGoogle Scholar
• 16 Hedner U, Lee CA. First 20 years with recombinant FVIIa (NovoSeven). Haemophilia 2011; 17 (1) e172-e182
  CrossrefPubMedGoogle Scholar
• 17 Franchini M, Zaffanello M, Veneri D. Recombinant factor VIIa. An update on its clinical use. Thromb Haemost 2005; 93 (6) 1027-1035
  PubMedGoogle Scholar
• 18 Franchini M. Recombinant factor VIIa: a review on its clinical use. Int J Hematol 2006; 83 (2) 126-138
  CrossrefPubMedGoogle Scholar
• 19 Dutton RP, Parr M, Tortella BJ , et al; CONTROL Study Group. Recombinant activated factor VII safety in trauma patients: results from the CONTROL trial. J Trauma 2011; 71 (1) 12-19
  CrossrefPubMedGoogle Scholar
• 20 Boffard KD, Riou B, Warren B , et al; NovoSeven Trauma Study Group. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma 2005; 59 (1) 8-15 , discussion 15–18
  CrossrefPubMedGoogle Scholar
• 21 Yank V, Tuohy CV, Logan AC , et al. Systematic review: benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications. Ann Intern Med 2011; 154 (8) 529-540
  CrossrefPubMedGoogle Scholar
• 22 Levi M, Levy JH, Andersen HF, Truloff D. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med 2010; 363 (19) 1791-1800
  CrossrefPubMedGoogle Scholar
• 23 Simpson E, Lin Y, Stanworth S, Birchall J, Doree C, Hyde C. Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. Cochrane Database Syst Rev 2012; 3: CD005011
  PubMedGoogle Scholar
• 24 Franchini M, Lippi G, Franchi M. The use of recombinant activated factor VII in obstetric and gynaecological haemorrhage. BJOG 2007; 114 (1) 8-15
  PubMedGoogle Scholar
• 25 Franchini M, Franchi M, Bergamini V, Salvagno GL, Montagnana M, Lippi G. A critical review on the use of recombinant factor VIIa in life-threatening obstetric postpartum hemorrhage. Semin Thromb Hemost 2008; 34 (1) 104-112
  Article in Thieme ConnectPubMedGoogle Scholar
• 26 Franchini M, Franchi M, Bergamini V , et al. The use of recombinant activated FVII in postpartum hemorrhage. Clin Obstet Gynecol 2010; 53 (1) 219-227
  CrossrefPubMedGoogle Scholar
• 27 Ahonen J. The role of recombinant activated factor VII in obstetric hemorrhage. Curr Opin Anaesthesiol 2012; 25 (3) 309-314
  CrossrefPubMedGoogle Scholar
• 28 WHO. WHO recommendations for the prevention and treatment of postpartum haemorrhage. http://apps.who.int/iris/bitstream/10665/75411/1/9789241548502_eng. pdf . Published 2012
  PubMedGoogle Scholar
• 29 Hellstern P. Production and composition of prothrombin complex concentrates: correlation between composition and therapeutic efficiency. Thromb Res 1999; 95 (4) (Suppl. 01) S7-S12
  CrossrefPubMedGoogle Scholar
• 30 Franchini M, Lippi G. Prothrombin complex concentrates: an update. Blood Transfus 2010; 8 (3) 149-154
  PubMedGoogle Scholar
• 31 Franchini M, Liumbruno GM, Lanzoni M , et al. Clinical use and the Italian demand for prothrombin complex concentrates. Blood Transfus 2013; 11 (Suppl. 04) s94-s100
  PubMedGoogle Scholar
• 32 Schöchl H, Nienaber U, Hofer G , et al. Goal-directed coagulation management of major trauma patients using thromboelastometry (ROTEM)-guided administration of fibrinogen concentrate and prothrombin complex concentrate. Crit Care 2010; 14 (2) R55
  CrossrefPubMedGoogle Scholar
• 33 Schöchl H, Nienaber U, Maegele M , et al. Transfusion in trauma: thromboelastometry-guided coagulation factor concentrate-based therapy versus standard fresh frozen plasma-based therapy. Crit Care 2011; 15 (2) R83
  CrossrefPubMedGoogle Scholar
• 34 Nienaber U, Innerhofer P, Westermann I , et al. The impact of fresh frozen plasma vs coagulation factor concentrates on morbidity and mortality in trauma-associated haemorrhage and massive transfusion. Injury 2011; 42 (7) 697-701
  CrossrefPubMedGoogle Scholar
• 35 Joseph B, Amini A, Friese RS , et al. Factor IX complex for the correction of traumatic coagulopathy. J Trauma Acute Care Surg 2012; 72 (4) 828-834
  PubMedGoogle Scholar
• 36 Fries D. The early use of fibrinogen, prothrombin complex concentrate, and recombinant-activated factor VIIa in massive bleeding. Transfusion 2013; 53 (Suppl. 01) 91S-95S
  CrossrefPubMedGoogle Scholar
• 37 Sørensen B, Spahn DR, Innerhofer P, Spannagl M, Rossaint R. Clinical review: Prothrombin complex concentrates–evaluation of safety and thrombogenicity. Crit Care 2011; 15: R201
  CrossrefPubMedGoogle Scholar
• 38 Palareti G, Leali N, Coccheri S , et al; Italian Study on Complications of Oral Anticoagulant Therapy. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Lancet 1996; 348 (9025) 423-428
  CrossrefPubMedGoogle Scholar
• 39 Diness V, Lund-Hansen T, Hedner U. Effect of recombinant human FVIIA on warfarin-induced bleeding in rats. Thromb Res 1990; 59 (6) 921-929
  CrossrefPubMedGoogle Scholar
• 40 Erhardtsen E, Nony P, Dechavanne M, Ffrench P, Boissel JP, Hedner U. The effect of recombinant factor VIIa (NovoSeven) in healthy volunteers receiving acenocoumarol to an International Normalized Ratio above 2.0. Blood Coagul Fibrinolysis 1998; 9 (8) 741-748
  CrossrefPubMedGoogle Scholar
• 41 Deveras RAE, Kessler CM. Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate. Ann Intern Med 2002; 137 (11) 884-888
  CrossrefPubMedGoogle Scholar
• 42 Sørensen B, Johansen P, Nielsen GL, Sørensen JC, Ingerslev J. Reversal of the International Normalized Ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophylaxis: clinical and biochemical aspects. Blood Coagul Fibrinolysis 2003; 14 (5) 469-477
  CrossrefPubMedGoogle Scholar
• 43 Rosovsky RP, Crowther MA. What is the evidence for the off-label use of recombinant factor VIIa (rFVIIa) in the acute reversal of warfarin? ASH evidence-based review 2008. Hematology (Am Soc Hematol Educ Program) 2008; •••: 36-38
  PubMedGoogle Scholar
• 44 Makris M, Greaves M, Phillips WS, Kitchen S, Rosendaal FR, Preston EF. Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemost 1997; 77 (3) 477-480
  Article in Thieme ConnectPubMedGoogle Scholar
• 45 Cartmill M, Dolan G, Byrne JL, Byrne PO. Prothrombin complex concentrate for oral anticoagulant reversal in neurosurgical emergencies. Br J Neurosurg 2000; 14 (5) 458-461
  CrossrefPubMedGoogle Scholar
• 46 Huttner HB, Schellinger PD, Hartmann M , et al. Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy: comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrates. Stroke 2006; 37 (6) 1465-1470
  CrossrefPubMedGoogle Scholar
• 47 Woo CH, Patel N, Conell C , et al. Rapid Warfarin reversal in the setting of intracranial hemorrhage: a comparison of plasma, recombinant activated factor VII, and prothrombin complex concentrate. World Neurosurg 2014; 81 (1) 110-115
  CrossrefPubMedGoogle Scholar
• 48 Imberti D, Barillari G, Biasioli C , et al. Emergency reversal of anticoagulation with a three-factor prothrombin complex concentrate in patients with intracranial haemorrhage. Blood Transfus 2011; 9 (2) 148-155
  PubMedGoogle Scholar
• 49 Sarode R, Milling Jr TJ, Refaai MA , et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation 2013; 128 (11) 1234-1243
  CrossrefPubMedGoogle Scholar
• 50 Hickey M, Gatien M, Taljaard M, Aujnarain A, Giulivi A, Perry JJ. Outcomes of urgent warfarin reversal with frozen plasma versus prothrombin complex concentrate in the emergency department. Circulation 2013; 128 (4) 360-364
  CrossrefPubMedGoogle Scholar
• 51 Leissinger CA, Blatt PM, Hoots WK, Ewenstein B. Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature. Am J Hematol 2008; 83 (2) 137-143
  CrossrefPubMedGoogle Scholar
• 52 Dentali F, Marchesi C, Pierfranceschi MG , et al. Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis. Thromb Haemost 2011; 106 (3) 429-438
  Article in Thieme ConnectPubMedGoogle Scholar
• 53 Franchini M, Mannucci PM. New anticoagulants for treatment of venous thromboembolism. Eur J Intern Med 2012; 23 (8) 692-695
  CrossrefPubMedGoogle Scholar
• 54 Mannucci PM, Franchini M. Old and new anticoagulant drugs: a minireview. Ann Med 2011; 43 (2) 116-123
  CrossrefPubMedGoogle Scholar
• 55 Gross PL, Weitz JI. New antithrombotic drugs. Clin Pharmacol Ther 2009; 86 (2) 139-146
  CrossrefPubMedGoogle Scholar
• 56 Franchini M, Mannucci PM. A new era for anticoagulants. Eur J Intern Med 2009; 20 (6) 562-568
  CrossrefPubMedGoogle Scholar
• 57 Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G ; American College of Chest Physicians. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2) e44S-e88S
  CrossrefPubMedGoogle Scholar
• 58 Dentali F, Riva N, Crowther M, Turpie AG, Lip GY, Ageno W. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation 2012; 126 (20) 2381-2391
  CrossrefPubMedGoogle Scholar
• 59 Van Ryn J, Litzenburger T, Waterman A , et al. Dabigatran anticoagulant activity is neutralized by an antibody selective to dabigatran in in vitro and in vivo models. J Am Coll Cardiol 2011; 57: E1130
  CrossrefPubMedGoogle Scholar
• 60 Lu G, DeGuzman FR, Lakhotia S, Hollenbach SJ, Phillips DR, Sinha U. Recombinant antidote for reversal of anticoagulation by factor Xa inhibitors. ASH Annual Meet Abstr 2008; 112: 983
  PubMedGoogle Scholar
• 61 Lu GP, Peng L, Hollenbach SJ , et al. Reconstructed recombinant factor Xa as an antidote to reverse anticoagulation by factor Xa inhibitors. J Thromb Haemost 2009; 7: 309
  PubMedGoogle Scholar
• 62 Zhou W, Schwarting S, Illanes S , et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke 2011; 42 (12) 3594-3599
  CrossrefPubMedGoogle Scholar
• 63 Godier A, Miclot A, Le Bonniec B , et al. Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model. Anesthesiology 2012; 116 (1) 94-102
  CrossrefPubMedGoogle Scholar
• 64 Escolar G, Arellano-Rodrigo E, Reverter JC , et al. Reversal of apixaban induced alterations of hemostasis by different coagulation factor concentrates: studies in vitro with circulating human blood. Circulation 2012; 126: 520-521
  CrossrefPubMedGoogle Scholar
• 65 Marlu R, Hodaj E, Paris A, Albaladejo P, Cracowski JL, Pernod G. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 2012; 108 (2) 217-224
  Article in Thieme ConnectPubMedGoogle Scholar
• 66 Liew A, Eikelboom JW, O'Donnell M, Hart RG. Assessment of anticoagulation intensity and management of bleeding with old and new oral anticoagulants. Can J Cardiol 2013; 29 (7) S34-S44
  CrossrefPubMedGoogle Scholar
• 67 Pragst I, Zeitler SH, Doerr B , et al. Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model. J Thromb Haemost 2012; 10 (9) 1841-1848
  CrossrefPubMedGoogle Scholar
• 68 Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124 (14) 1573-1579
  CrossrefPubMedGoogle Scholar
• 69 Perzborn E, Gruber A, Tinel H , et al. Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates. Thromb Haemost 2013; 110 (1) 162-172
  Article in Thieme ConnectPubMedGoogle Scholar
• 70 Escolar G, Arellano-Rodrigo E, Reverter JC , et al. Reversal of apixaban induced alterations of hemostasis by different coagulation factor concentrates: studies in vitro with circulating human blood. Blood 2012; 190 (21) Abstract 2263
  PubMedGoogle Scholar
• 71 Arellano-Rodrigo E, Galan AM, Sanz V , et al. Alterations induced by rivaroxaban on hemostasis can be reversed by different coagulation factor concentrates: in vitro experimental studies with steady and circulating human blood. J Thromb Haemost 2013; 11 (Suppl. 02) 953
  PubMedGoogle Scholar
• 72 Khoo TL, Weatherburn C, Kershaw G, Reddel CJ, Curnow J, Dunkley S. The use of FEIBA® in the correction of coagulation abnormalities induced by dabigatran. Int J Lab Hematol 2013; 35 (2) 222-224
  CrossrefPubMedGoogle Scholar
• 73 Escolar G, Fernandez-Gallego V, Arellano-Rodrigo E , et al. Reversal of apixaban induced alterations in hemostasis by different coagulation factor concentrates: significance of studies in vitro with circulating human blood. PLoS ONE 2013; 8 (11) e78696
  CrossrefPubMedGoogle Scholar